e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients
J. Pepke-Zaba, M. Brown, T. Parpia, C. Gilbert, G. Burgess (Cambridge, Sandwich, United Kingdom)
Source:
Annual Congress 2005 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Thematic Poster Session
Number:
3621
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Pepke-Zaba, M. Brown, T. Parpia, C. Gilbert, G. Burgess (Cambridge, Sandwich, United Kingdom). Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients. Eur Respir J 2005; 26: Suppl. 49, 3621
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Health-related quality of life in patients with pulmonary arterial hypertension
Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Year: 2011
Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension
Source: Eur Respir J 2011; 38: 608-616
Year: 2011
Measurement of quality of life in pulmonary hypertension and its significance
Source: Eur Respir J 2006 Oct 01;28(4):808-815
Year: 2006
Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR
Source: Eur Respir J, 57 (2) 2000414; 10.1183/13993003.00414-2020
Year: 2021
Relationship of quality of life and life expectancy with tolerance to physical exercises and cardio respiratory parameters in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases
Year: 2013
Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
The assessment of life expectancy of patients with primary pulmonary hypertension (PPH)
Source: Eur Respir J 2003; 22: Suppl. 45, 582s
Year: 2003
emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension
Source: Eur Respir J 2014; 43: 1106-1113
Year: 2014
Em
PH
asis-10 is associated with clinical outcome measures in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study
Source: ERJ Open Res, 7 (3) 00617-2020; 10.1183/23120541.00617-2020
Year: 2021
Pulmonary arterial hypertension: the burden of disease and impact on quality of life
Source: Eur Respir Rev 2015; 24: 621-629
Year: 2015
Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 563s
Year: 2003
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
The effect of pulmonary rehabilitation on health-related quality of life in patients with pulmonary sarcoidosis
Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings
Year: 2018
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Year: 2019
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
Source: Eur Respir J 2010; 35: 118-123
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept